
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5322224/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serious Infections and Mortality in Association With Therapies for Crohn's Disease: TREAT Registry. Clinical Gastroenterology and Hepatology, 2006, 4, 621-630.	2.4	831
2	Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREATâ,,¢ Registry. American Journal of Gastroenterology, 2012, 107, 1409-1422.	0.2	652
3	Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology, 2001, 96, 2929-2933.	0.2	384
4	Intravenous Cyclosporin in Ulcerative Colitis: A Five-Year Experience. American Journal of Gastroenterology, 1999, 94, 1587-1592.	0.2	317
5	An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease. American Journal of Gastroenterology, 2004, 99, 1984-1989.	0.2	249
6	A Meta-Analysis and Overview of The Literature on Treatment Options for Left-Sided Ulcerative Colitis and Ulcerative Proctitis. American Journal of Gastroenterology, 2000, 95, 1263-1276.	0.2	244
7	Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?. Gastrointestinal Endoscopy, 2007, 65, 998-1004.	0.5	237
8	Infliximab in Crohn's Disease: First Anniversary Clinical Experience. American Journal of Gastroenterology, 2000, 95, 3469-3477.	0.2	207
9	Absence of Infliximab in Infants and Breast Milk From Nursing Mothers Receiving Therapy for Crohn's Disease Before and After Delivery. Journal of Clinical Gastroenterology, 2009, 43, 613-616.	1.1	145
10	Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology, 2021, 160, 1131-1139.	0.6	145
11	Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies. , 2019, 7, 1.		143
12	The Cost of Hospitalization in Crohn's Disease. American Journal of Gastroenterology, 2000, 95, 524-530.	0.2	128
13	Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflammatory Bowel Diseases, 2008, 14, 738-743.	0.9	122
14	Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflammatory Bowel Diseases, 2009, 15, 1302-1307.	0.9	113
15	Infliximab Decreases Resource Use Among Patients With Crohn's Disease. Journal of Clinical Gastroenterology, 2002, 35, 151-156.	1.1	106
16	Medical management of left-sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials. Inflammatory Bowel Diseases, 2006, 12, 979-994.	0.9	97
17	Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clinical Gastroenterology and Hepatology, 2018, 16, 99-105.	2.4	97
18	Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001–2002. Current Medical Research and Opinion, 2006, 22, 989-1000.	0.9	95

RUSSELL D COHEN

#	Article	IF	CITATIONS
19	Side-to-Side Isoperistaltic Strictureplasty in Extensive Crohn's Disease. Annals of Surgery, 2000, 232, 401-408.	2.1	90
20	Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. Inflammatory Bowel Diseases, 2018, 24, 490-501.	0.9	87
21	Quality of Life After Proctocolectomy With Ileoanal Anastomosis for Patients With Ulcerative Colitis. Journal of Clinical Gastroenterology, 2006, 40, 669-677.	1.1	85
22	Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis,. American Journal of Clinical Nutrition, 2016, 104, 113-120.	2.2	78
23	Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 486-493.	2.4	76
24	Mesalamine delivery systems: do they really make much difference?. Advanced Drug Delivery Reviews, 2005, 57, 281-302.	6.6	73
25	A Comparison of the Quality of Life in Patients with Severe Ulcerative Colitis After Total Colectomy Versus Medical Treatment with Intravenous Cyclosporin. Inflammatory Bowel Diseases, 1999, 5, 1-10.	0.9	67
26	Managing Immunogenic Responses to Infliximab. Drugs, 2004, 64, 1767-1777.	4.9	67
27	Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 104-110.	2.4	60
28	Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: Summary statement. Inflammatory Bowel Diseases, 2006, 12, 972-978.	0.9	59
29	Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. Journal of Crohn's and Colitis, 2017, 11, 785-791.	0.6	57
30	Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. Digestive Diseases and Sciences, 2018, 63, 1294-1301.	1.1	53
31	The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflammatory Bowel Diseases, 2018, 24, 502-509.	0.9	50
32	Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. Digestive Diseases and Sciences, 2019, 64, 3596-3601.	1.1	50
33	Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clinical Therapeutics, 1998, 20, 1009-1028.	1.1	49
34	Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflammatory Bowel Diseases, 2001, 7, S17-S22.	0.9	47
35	Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. Journal of Medical Economics, 2015, 18, 447-456.	1.0	47
36	The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. Journal of Crohn's and Colitis, 2020, 14, 192-204.	0.6	45

RUSSELL D COHEN

#	Article	IF	CITATIONS
37	Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment. Inflammatory Bowel Diseases, 2008, 14, 1707-1714.	0.9	39
38	Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS ONE, 2017, 12, e0182900.	1.1	39
39	Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroidâ€refractory ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 637-643.	1.9	37
40	Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointestinal Endoscopy, 2019, 90, 269-275.	0.5	36
41	Systematic Review. Inflammatory Bowel Diseases, 2015, 21, 1719-1736.	0.9	35
42	Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflammatory Bowel Diseases, 2018, 24, 849-860.	0.9	34
43	Natalizumab in Crohn's Disease. Inflammatory Bowel Diseases, 2013, 19, 621-626.	0.9	33
44	The Effect of Maternal Peripartum Anti-TNFα Use on Infant Immune Response. Digestive Diseases and Sciences, 2016, 61, 1622-1627.	1.1	33
45	Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 1158-1162.	0.6	30
46	Predictors of adalimumab dose escalation in patients with crohn's disease at a tertiary referral center. Inflammatory Bowel Diseases, 2012, 18, 10-16.	0.9	29
47	Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflammatory Bowel Diseases, 2016, 22, 631-637.	0.9	27
48	Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointestinal Endoscopy, 2018, 87, 1304-1309.	0.5	25
49	The Incidence and Predictors of Lupus-like Reaction in Patients with IBD Treated with Anti-TNF Therapies. Inflammatory Bowel Diseases, 2013, 19, 2778-2786.	0.9	24
50	Mucosal Healing Is Associated with Improved Long-term Outcome of Maintenance Therapy with Natalizumab in Crohn's Disease. Inflammatory Bowel Diseases, 2013, 19, 2577-2583.	0.9	24
51	Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. Journal of Crohn's and Colitis, 2019, 13, 1105-1110.	0.6	24
52	Nicotine in Ulcerative Colitis. BioDrugs, 1996, 5, 169-174.	0.7	23
53	Crohn's Disease and Takayasu's Arteritis. Journal of Clinical Gastroenterology, 2002, 34, 454-456.	1.1	22
54	Optimizing conventional therapy for inflammatory bowel disease. Current Gastroenterology Reports, 2008, 10, 585-590.	1.1	22

#	Article	IF	CITATIONS
55	Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clinical Gastroenterology and Hepatology, 2015, 13, 1919-1925.	2.4	21
56	Efficacy and Follow-up of Segmental or Subtotal Colectomy inÂPatients With Colitis-Associated Neoplasia. Clinical Gastroenterology and Hepatology, 2019, 17, 205-206.	2.4	21
57	Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. Inflammatory Bowel Diseases, 2016, 22, 1027-1031.	0.9	20
58	Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. Journal of Clinical Gastroenterology, 2018, 52, 537-544.	1.1	20
59	Medical therapy for ulcerative colitis: The state of the art and beyond. Current Gastroenterology Reports, 2004, 6, 488-495.	1.1	19
60	Collagenous Gastritis: An Unusual Association With Profound Weight Loss. Archives of Pathology and Laboratory Medicine, 2004, 128, 229-232.	1.2	19
61	Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 236-241.	0.9	18
62	A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflammatory Bowel Diseases, 0, 5, 1-10.	0.9	18
63	Assessment of Variables Associated with Smoking Cessation in Crohn's Disease. Digestive Diseases and Sciences, 2012, 57, 1026-1032.	1.1	17
64	Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. Current Treatment Options in Gastroenterology, 2007, 10, 185-194.	0.3	15
65	Correlation of nuclear morphometry and DNA ploidy in rectal cancer. Diseases of the Colon and Rectum, 1991, 34, 449-454.	0.7	14
66	Evolving medical therapies for ulcerative colitis. Current Gastroenterology Reports, 2002, 4, 497-505.	1.1	14
67	Approach to Optimize Anti-TNF-α Therapy in Patients With IBD. Current Treatment Options in Gastroenterology, 2016, 14, 83-90.	0.3	14
68	Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients. Diseases of the Colon and Rectum, 2019, 62, 463-469.	0.7	14
69	A comparison of the risk of postoperative recurrence between Africanâ€American and Caucasian patients with Crohn's disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 933-940.	1.9	12
70	Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. Inflammatory Bowel Diseases, 2021, 27, 1008-1016.	0.9	12
71	First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchange. Journal of Clinical Apheresis, 2002, 17, 204-206.	0.7	11
72	Incidence and Predictors of Clinical Response, Re-induction Dose, and Maintenance Dose Escalation with Certolizumab Pegol in Crohn's Disease. Inflammatory Bowel Diseases, 2014, 20, 1722-1728.	0.9	11

#	Article	lF	CITATIONS
73	Immunomodulatory agents and other medical therapies in inflammatory bowel disease. Current Opinion in Gastroenterology, 1995, 11, 321-330.	1.0	10
74	Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Digestive Diseases and Sciences, 2018, 63, 1016-1024.	1.1	10
75	What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients. Gastroenterology and Hepatology, 2015, 11, 657-65.	0.2	10
76	Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis. Intestinal Research, 2022, 20, 240-250.	1.0	10
77	Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis. Therapeutics and Clinical Risk Management, 2007, 3, 919-27.	0.9	9
78	Evolving medical therapies for ulcerative colitis. Current Gastroenterology Reports, 2001, 3, 464-470.	1.1	8
79	Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine. Drug Design, Development and Therapy, 2011, 5, 111.	2.0	8
80	Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 1365-1372.	1.9	8
81	The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn's Disease. Digestion, 2021, 102, 767-775.	1.2	8
82	Infliximab decreases resource utilization in patients with Crohn's disease. American Journal of Gastroenterology, 2000, 95, 2499-2500.	0.2	7
83	How should we treat severe acute steroid-refractory ulcerative colitis?. Inflammatory Bowel Diseases, 2009, 15, 150-151.	0.9	7
84	Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflammatory Bowel Diseases, 2020, 27, 1620-1625.	0.9	7
85	Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohnâ \in ^M s disease. Intestinal Research, 2022, 20, 303-312.	1.0	7
86	Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonistâ€maintained clinical remission. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 2090-2095.	1.4	6
87	Postoperative management of ulcerative colitis and crohn's disease. Current Gastroenterology Reports, 2005, 7, 492-499.	1.1	5
88	Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. Expert Review of Gastroenterology and Hepatology, 2007, 1, 101-112.	1.4	5
89	IBD: the drugs workbut do the patients?. American Journal of Gastroenterology, 2003, 98, 722-723.	0.2	4
90	Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflammatory Bowel Diseases, 2018, 24, 1291-1297.	0.9	3

#	Article	IF	CITATIONS
91	Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2785-2793.	1.4	3
92	Management of refractory ulcerative colitis. Current Treatment Options in Gastroenterology, 2006, 9, 234-245.	0.3	2
93	Infliximab as First-Line Therapy for Severe Crohn's Disease?. Inflammatory Bowel Diseases, 2002, 8, 58-59.	0.9	1
94	Response:. Gastrointestinal Endoscopy, 2008, 67, 1009-1010.	0.5	1
95	P-074â€ f Age of Diagnosis Is Associated with the Severity of Adverse Effects to Therapy in Crohnâ€ [™] s Disease Patients. Inflammatory Bowel Diseases, 2013, 19, S55.	0.9	1
96	Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings?. Alimentary Pharmacology and Therapeutics, 2020, 52, 559-560.	1.9	1
97	UC CANCERS IN PSC: RIGHT SIDED OR WRONG?. Inflammatory Bowel Diseases, 1998, 4, 330.	0.9	Ο
98	PREVALENCE, PATTERN, AND PREDICTORS OF ALCOHOL (ETOH) USE FOLLOWING LIVER TRANSPLANTATION (OLT) Transplantation, 2000, 69, S390.	0.5	0
99	Transcending therapeutic conventions: New realities in the treatment of Crohn's disease. Inflammatory Bowel Diseases, 2001, 7, S1-S1.	0.9	0
100	Direct and Indirect Utilization and Costs Associated With Ulcerative Colitis. Inflammatory Bowel Diseases, 2012, 18, S41.	0.9	0
101	Natalizumab in Crohn's Disease: Results from a U.S. Tertiary IBD Center. American Journal of Gastroenterology, 2012, 107, S672-S673.	0.2	0
102	Nonmedical Switching of Biosimilars in Patients With Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2017, 13, 697-699.	0.2	0
103	A Comprehensive Review of Topical Therapies for Distal Ulcerative Colitis. Gastroenterology and Hepatology, 2020, 16, 21-27.	0.2	0
104	Rare and Well Done: Endoscopic Control of Colonic Hemorrhage in Severe Ulcerative Colitis. Digestive Diseases and Sciences, 2022, 67, 805-809.	1.1	0